MTX based chemotherapy
Phase 2Small molecule
MTX based chemotherapy is one of 45 small molecule programs targeting Central Nervous System Lymphoma. It is currently in Phase 2.
1
Indications
1
Total Trials
1
Active Trials
44
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
83 competitors in Central Nervous System Lymphoma
#DrugCompanyPhaseTrials
1Rituxan
RochePhase 3
Temodar
CCidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Phase 3
Trexall
Alnylam PharmaceuticalsPhase 2
Nublexa
BBeijing InnoCare Pharma Tech Co., Ltd.
Phase 3
Cytosar
TevaPhase 2
Opdivo
Bristol-Myers SquibbPhase 2
Keytruda
Merck & Co.Phase 2
Oncovin
Eli LillyPhase 2
Fludara
SanofiPhase 2
Gazyva
RochePhase 2
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for MTX based chemotherapy. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Phase 2[1]
- Company
- IInstitut Curie